阿德福韦酯在治疗乙肝肝硬化伴肝源性糖尿病中的作用  

Antiviral therapy of Adefovir Dipivoxil in patients with liver cirrhosis after hepatitis B complicated by hepatic diabetes

作　　者：巫继[1] 陈嵩[1] 

机构地区：[1]重庆市第三军医大学西南医院全军感染病研究所,重庆400038

出　　处：《中国医药导报》2011年第28期180-181,共2页China Medical Herald

摘　　要：目的:观察抗病毒治疗乙肝肝硬化伴肝源性糖尿病的临床疗效。方法:选取82例乙肝肝硬化伴肝源性糖尿病患者,随机分为观察组与对照组,每组各41例,其中,观察组给予阿德福韦酯抗病毒治疗,对照组给予内科常规治疗,比较两组治疗前后肝功能指标及血糖水平。结果:观察组总有效率为78.05%,对照组总有效率仅有35.71%,两组总有效率比较,差异具有统计学意义(P<0.01)。结论:抗病毒治疗乙肝肝硬化伴肝源性糖尿病,肝功能恢复良好,血糖控制理想,用药安全,不良反应少,值得临床推广应用。Objective： To observe the clinical effect of antiviral therapy in patients with liver cirrhosis after hepatitis B complicated by hepatic diabetes.Methods： 82 patients with liver cirrhosis after hepatitis B complicated by hepatic diabetes were randomly divided into the observation group and control group,each group was 41 cases respectively.The observation group were given the antiviral therapy of Adefovir Dipivoxil,while the control group were given the conventional medical therapy,then the liver function tests and blood glucose level were compared before and after the treatment between two groups.Results： The response rate of the observation group was 78.05%,while there was only 35.71% in the control group,with the significant difference（P〈0.01）.Conclusion： The antiviral therapy in patients with liver cirrhosis after hepatitis B complicated by hepatic diabetes leads to the good recovery of liver function,ideal control of blood glucose,safe administration and little adverse reactions,and is worthy to be generalized clinically.

关 键 词：抗病毒治疗 乙肝肝硬化 肝源性糖尿病 

分 类 号：R512.62[医药卫生—内科学]